Edition:
United Kingdom

People: Advaxis Inc (ADXS.OQ)

ADXS.OQ on NASDAQ Stock Exchange Global Select Market

0.31USD
13 Sep 2019
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$0.31
Open
$0.31
Day's High
$0.31
Day's Low
$0.29
Volume
373,427
Avg. Vol
146,692
52-wk High
$14.55
52-wk Low
$0.26

Henderson, Molly 

Ms. Molly Henderson is Chief Financial Officer, Executive Vice President of the Company. She joins the company having over 20 years of operating company experience, most recently with Iovance Biotherapeutics, (formerly Lion Biotechnologies, Inc.) (Nasdaq: IOVA), an immuno-oncology company where she was responsible for all SEC and financial related matters including raising $100 million in equity capital. In her over twenty years of financial experience, Ms. Henderson brings to Advaxis a demonstrated set of skills that includes operational efficiency, fund raising, M&A evaluation, investor relations, accounting and financial controls. Prior to Iovance, for more than a decade Ms. Henderson was Chief Financial Officer of VirtualScopics, Inc. (formerly Nasdaq: VSCP) during a period when the company evolved from an early stage company to a publicly-traded, profitable business serving the biotechnology and pharmaceutical industries. Earlier in her career Ms. Henderson was Corporate Controller at Ultralife Corporation and an expert advisor to entrepreneurs in Switzerland. She began her career as an audit manager at PricewaterhouseCoopers. Ms. Henderson holds an MBA and a BS in Accounting from the University at Buffalo. She is a licensed CPA (inactive) in the State of New York.

Basic Compensation

Total Annual Compensation, USD 181,917
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 339,954
Fiscal Year Total, USD 521,871

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

David Sidransky

2,020,800

Kenneth Berlin

1,797,460

James Patton

--

Molly Henderson

521,871

Roni Appel

144,615

Samir Khleif

--
As Of  31 Oct 2018